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ABSTRACT
Objective: To explore the association of hypothalamic–pituitary–adrenal activity with ovarian functioning in women
with and without chronic abdominal pain (CAP).
Design and Setting: A secondary data analysis was performed with data from female participants in a natural history
protocol at the National Institutes of Health.
Participants: A total of 36 women (age range ¼ 19–39 years, mean ¼ 27.11 years) were included in the study.
Methods: This pilot study was conducted with a subset of participants enrolled in a natural history protocol conducted
in the Hatfield Clinical Research Center at the National Institutes of Health. The parent study included participants with
and without CAP who provided a 5-hour urine sample for determination of cortisol levels and serum samples for
determination of circulating levels of cortisol, luteinizing hormone, and follicle-stimulating hormone. CAP was defined
as presence or absence of chronic pain for at least 6 months and was determined via self-report.
Results: Anti-Müllerian hormone (AMH) concentrations declined significantly with age as expected. When AMH levels
were dichotomized as normal or abnormal (defined as higher or lower than age-specific normative ranges,
respectively), there were significant associations between abnormal AMH levels and CAP and urine cortisol levels.
Participants with CAP or low urine cortisol levels were significantly more likely to have abnormal AMH levels.
Conclusion: Results suggest that chronic abdominal pain and hypothalamic–pituitary–adrenal dysregulation may be
associated with abnormal AMH levels.
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O

ne in ten women faces early ovarian senescence, which means that around 10% of
women will experience fertility problems related to
diminished ovarian reserve by their early to midthirties (Maheshwari, Bhattacharya, & Johnson,
2008). Ovarian reserve, the number of remaining
follicles in the ovary, declines naturally with age;
however, researchers recently showed that age
alone is not an accurate indicator of reproductive
age and that other factors may be implicated in the
depletion of the ovarian follicle pool (van Disseldorp
et al., 2008). Thus, the identification of factors that
contribute to the decline of ovarian reserve may aid
in the prevention and early detection of follicular
depletion, premature ovarian failure, and impaired
fertility (Lie Fong et al., 2009).
Dysregulation of the hypothalamic–pituitary–
adrenal (HPA) axis accelerates biological aging
and may contribute to ovarian senescence (Miller,

Chen, & Parker, 2011; Révész et al., 2014).
Chronic physiologic stress, such as chronic
abdominal pain (CAP) can lead to HPA dysregulation (Révész et al., 2014). Women report CAP
more frequently than men in the United States
(2:1), and CAP is estimated to occur in 14% of
women worldwide (Lovell & Ford, 2012; Peace
et al., 2012). Individuals with chronic pain often
exhibit HPA dysregulation (Simons, Elman, &
Borsook, 2014; Vachon-Presseau et al., 2013),
and for this reason, CAP is an ideal model to
explore the influence of HPA activity on ovarian
function. In this pilot study, we explored the
association between chronic pain, a model of
HPA dysregulation, and ovarian reserve.

Anti-Müllerian Hormone: A
Measure of Ovarian Reserve
Anti-Müllerian hormone (AMH) is produced by the
granulosa cells of growing ovarian follicles until
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they have reached the size and differentiation
state at which they may be selected for dominance (La Marca et al., 2012). Kelsey, Wright,
Nelson, Anderson, and Wallace (2011) validated serum AMH as a biomarker of ovarian
reserve and showed changes in AMH levels
throughout a female’s lifespan. AMH levels
steadily increase from conception, reach their
peak at 24.5 years of age, and then steadily
decline until menopause (Kelsey et al., 2011).
Two properties of AMH make it particularly useful
in the study of ovarian reserve: the decline of
AMH levels in serum is the earliest indication of a
decline in ovarian reserve, and AMH levels
remain stable throughout the menstrual cycle
(Shaw et al., 2011).
AMH has been used to predict ovarian response
to reproductive assistive technologies and to
determine the effect of chemotherapy and radiation on ovarian function. More recent data supported the association between AMH and the
onset of menopause, significantly expanding the
potential application of this measure as a
biomarker of ovarian function (van Disseldorp
et al., 2008). Factors associated with lower
serum concentrations are obesity (Malhotra,
Bahadur, Singh, Kalaivani, & Mittal, 2013;
Steiner, Stanczyk, Patel, & Edelman, 2010), oral
contraceptive use, (Dewailly et al., 2014; Steiner
et al., 2010), and pregnancy (Nelson, Stewart,
Fleming, & Freeman, 2010). However, it is not
known if chronic pain or HPA dysregulation affect
ovarian reserve.

HPA Dysregulation, Stress, and
Ovarian Function
HPA dysregulation due to repeated or prolonged
stressors, such as chronic pain, stimulates
cortisol secretion, reducing pulsatile luteinizing
hormone (LH) secretion and interrupting the
follicular phase of the menstrual cycle (Breen &
Mellon, 2014). At homeostatic levels, cortisol
contributes to steroid biosynthesis and maintenance of gonadotropin release; elevated cortisol
levels suppress gonadotropin-releasing hormone
secretion at the level of the pituitary and
increases rates of follicle atresia (Whirledge &
Cidlowski, 2010; Whirledge & Cidlowski, 2013).
Allsworth, Zierler, Krieger, and Harlow (2001)
were among the first to investigate the effect
of chronic stress on ovarian reserve. They examined whether ovarian hormone levels (folliclestimulating hormone [FSH] and estradiol)
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The identification of factors that contribute to the decline
of ovarian reserve may help detect and prevent follicular
depletion, premature ovarian failure, and impaired fertility.

indicative of menopausal changes were observed
at an earlier age among 732 women (ages 36–44
years) who experienced physical or sexual
violence compared with women who reported no
exposure to violence. More extreme levels of FSH
and estradiol in relation to abuse history among
premenopausal women ages 41–45 years were
observed, whereas little difference was seen for
younger women. Allsworth et al. offered a potential
biological explanation for the association between
abuse history and ovarian function: stress activates the HPA axis and stimulates glucocorticoid
secretion, which in turn inhibits the synthesis and
release of gonadotropin-releasing hormone, LH,
and FSH. However, Allsworth et al. did not include
a biomarker of stress in the study and, as a result,
were unable to examine this proposed biological
mechanism.
Pal, Bevilacqua, and Santoro (2010) expanded
the work of Allsworth et al. (2001) and examined
associations between acute (serum cortisol) and
chronic (history of abuse and/or drug use) psychosocial stress and biomarkers of ovarian
reserve (FSH and Müllerian-inhibiting substance
[now referred to as AMH]) in 89 premenopausal
women with infertility who were younger than 42
years. Women were considered to have diminished ovarian reserve (DOR) if they had early
follicular phase (days 1–3) FSH levels greater than
10 mIU/ml and/or poor ovarian response during
attempts at ovarian hyperstimulation. Those with
chronic stress had reduced ovarian reserve
parameters: higher FSH level (p ¼ .051) and
significantly lower Müllerian-inhibiting substance
levels (p ¼ .034) and were 3 times more likely to
have a diagnosis of DOR (p ¼ .025). However,
no association was observed between serum
cortisol levels and DOR. Pal et al. concluded that
chronic but not current stress was associated with
DOR. They proposed inappropriate HPA activation as a plausible explanation for this association.
Because a biomarker of chronic stress was not
included in the study, they were unable to provide
evidence to support this theory.
Although it is well established that psychological
stress interrupts normal reproductive functioning
(An, Sun, Li, Zhang, & Ji, 2013; Kalantaridou et al.,
2010; O’Connor et al., 2011; Whirledge &
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Cidlowski, 2013), the biological mechanisms
underlying this effect are poorly understood (Bleil
et al., 2012a, 2012b; Lynch, Sundaram, Buck
Louis, Lum, & Pyper, 2012). Our purpose in this
pilot study was to explore the association between
HPA activity and ovarian reserve (as measured
by AMH concentrations) in women with CAP.
Because CAP is associated with HPA dysregulation, we hypothesized that women with CAP would
exhibit abnormal AMH concentrations.

Theoretical Framework
The theoretical framework used to guide this study
was life history (Whirledge & Cidlowski, 2013). Life
history theory posits that the allocation of biological resources is a trade-off between survival and
reproduction. The intrinsic and extrinsic environments of the organism influence the timing of
puberty, fertility outcomes, and reproductive lifespan. The division of resources is mediated
through HPA activation. HPA activation leads to an
increase in glucocorticoids, directing resources to
vital physiologic activities such as energy mobilization, cardiac output, and cognition. At normal
physiologic levels, glucocorticoids promote
reproductive function, but in circumstances of
prolonged stress, such as chronic pain, prolonged exposure to increased levels of glucocorticoids suppresses gonadotropin release.

Methods
Study Population
The protocol was approved by the institutional
review board at the National Institutes of Health
(Clinicaltrial.gov #NCT00824941). This pilot
study was conducted using a subset of participants enrolled in a natural history protocol
(Clinicaltrial.gov #NCT00824941) conducted in
the Hatfield Clinical Research Center at the
National Institutes of Health. The parent study
included participants who completed the Sociodemographic Questionnaire developed by the
Center for Research in Chronic Disorders,
University of Pittsburgh School of Nursing
(1999) and provided urine and serum samples.
For this pilot study, only women between the
ages of 19 and 39 years who had their menses
for at least 2 years were included. Exclusion
criteria were history of organic gastrointestinal
disease; cardiac, pulmonary, neurologic, renal,
endocrine, or gynecologic pathology; taking
medications for gastrointestinal symptoms daily
or other medications that would alter serotonin,
catecholamines, or cortisol; work during the late
evening and night shifts; severe comorbid pain or
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psychiatric conditions; intake of more than
300 mg of caffeine-containing beverages or food
in the afternoon/evening or more than 2 servings
of alcohol-containing beverages every day; unable to physically use the touch screen for the
purpose of the study; visually impaired or institutionalized; or pregnant or lactating. A total of 36
women (33.3% Black or African American,
47.2% White, 19.4% Asian/other ethnicity) between the ages of 19 and 39 years with mean age
27.11  5.03 were included in the study. All
participants were between days 3 and 7 of their
menstrual cycles.

Data Collection
Participants enrolled in the parent study
completed the sociodemographic questionnaire
electronically. Whole blood was collected
between the hours of 0800 and 1000, and a
5-hour urine sample was collected between the
hours of 1000 and 1500. Whole-body air
displacement plethysmography, which is used to
measure body fat percentage, was completed on
all participants. Body fat of 30% or greater was
categorized as high body fat and less than
30% as low body fat. Urine cortisol was measured
via liquid chromatography–tandem mass spectrometry. Cortisol secretion follows a diurnal
pattern, and levels peak in the morning and
steadily decrease throughout the day (Hannibal &
Bishop, 2014). Thus, 5-hour urine cortisol test
results reflect a time-averaged measure of adrenocortical function. Serum was analyzed for
circulating levels of cortisol, FSH, and LH. CAP
was defined as self-reported presence or
absence of abdominal pain for at least 6 months
and was confirmed during the clinical visit by
using
the
Gastrointestinal
Pain
Pointer
(Henderson et al., 2015).

AMH
For this pilot study, in addition to the measures
included in the parent study as described earlier,
the AMH Gen II ELISA (Beckman Coulter, Inc.,
Brea, CA) was used to measure AMH concentrations in stored serum samples of 36 women per
the manufacturer’s instructions. The AMH Gen II
ELISA has a sensitivity of 0.57 pmol/l, and the
intra-assay coefficient of variation was 4.5%. The
validated model of serum AMH by Kelsey et al.
(2011) and the nomogram with normative values
for age published by La Marca et al. (2012) were
used to interpret AMH levels. Continuous AMH
levels were used to investigate associations
between AMH, CAP, serum and urinary cortisol,
and body fat. A dichotomous AMH variable
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Characteristic

Overall (n ¼ 36)

Age in years

27.11  5.03

Pain (n ¼ 17)
28  3.82

% body fat

31.99  8.85

FSH level (U/L)
LH level (U/L)

No Pain (n ¼19)

p

High Body Fat (n ¼ 22)

Low Body Fat (n ¼ 14)

p

26.32  5.9

.310

28.64  4.87

24.71  4.44

.019*

33.83  7.76

30.13  9.77

.220

37.68  5.71

22.75  4.05

<.001***

4.50  2.14

4.5  2.44

4.51  1.96

.990

4.84  2.2

3.99  2.08

.250

3.46  2.42

3.72  3.08

.790

10.76  4.59

11.75  5.46

.580

31.92  27.01

55.51  67.69

.090

3.9  3.43

4.27  2.64

.290

Normal AMH (n ¼ 31)

p

29  2.92

26.81  5.26

.320

34.68  9.43

31.42  8.95

.410

3.68  1.68

4.64  2.23

.340

3.87  2.7

1.68  1.29

.120

13.28  5.37

10.8  4.82

.340

.870

16.64  10.94

44.69  49.48

.040*

.810

5.88  7.13

3.75  1.97

.490

3.64  2.66

2.65  2.25

4.38  2.78

.048

Serum cortisol (mg/dl)

11.06  4.85

12.14  5.27

10.26  4.49

.260

Urine cortisol level (nmol)

40.68  46.92

29.59  29.17

51.16  57.99

.022

4.05  3.11

4.31  4.16

3.81  1.81

.504

Overall (n ¼ 36)

OC Use (n ¼ 12 )

No OC Use (n ¼ 24)

p

Age in years

27.11  5.03

26.17  3.76

27.58  5.57

.510

% body fat

31.99  8.85

29.6  7.8

33.02  9.43

.370

FSH level (U/L)

4.50  2.14

2.99  1.93

5.26  1.89

.002

LH level (U/L)

3.64  2.66

1.58  2.34

4.56  2.24

<.001***

Serum cortisol level (mg/dl)

11.06  4.85

16.28  3.63

8.58  3.09

<.001

Urine cortisol level (nmol)

40.68  46.92

32.88  23.41

44.75  55.48

4.05  3.11

4.47  4.5

3.83  2.21

AMH level (ng/ml)

AMH level (ng/ml)

*

*

Abnormal AMH (n ¼ 5)

**

***
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Table 1: Clinical and Demographic Data

Note. AMH ¼ Anti-Müllerian hormone; FSH ¼ follicle stimulating hormone; LH ¼ luteinizing hormone; OC ¼ oral contraceptive.
*
p < .05. **p < .01. ***p < .001.
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Hypothalamic–pituitary–adrenal dysregulation may
contribute to ovarian dysfunction as expressed by
abnormal anti-Müllerian hormone levels in women with
chronic abdominal pain.

(normal or abnormal) was also created for contingency analysis. Abnormal AMH values were
defined as values that fell above or below the
normative age-specific ranges published by La
Marca et al.

FSH (p ¼ .002) and LH (p # .001) and higher
serum cortisol levels (p # .001).
CAP was negatively associated with urine cortisol
levels (p ¼ .02). Participants with CAP also had
significantly lower LH levels. As expected, oral
contraceptive use was associated with lower LH
and FSH levels. Oral contraceptive use was also
associated with higher serum cortisol levels. Previous studies have shown this association; exogenous estrogens in oral contraceptive pills
increase corticosteroid-binding globulin and total
plasma cortisol concentrations (Jung et al., 2011).

Statistical Analysis
Descriptive analyses were performed for
demographic variables using grouping factors:
high ($30%) and low (<30%) body fat, presence or absence of CAP, oral contraceptive
use, and AMH category (normal or abnormal).
Body fat (Freeman et al., 2007; Malhotra et al.,
2013; Steiner et al., 2010) and oral contraceptive use (La Marca et al., 2010; Shaw
et al., 2011) were included as grouping factors in the descriptive analysis because of prior
evidence of their association with abnormal
AMH levels. CAP was included to explore differences between participants with and without
chronic pain.
Multiple linear regression was used to explore
associations between serum AMH concentration
and serum and urine cortisol, FSH and LH, body
fat, and CAP with and without adjusting for age
as a covariate in the model. A contingency
analysis was also conducted to evaluate the
association between categorized AMH levels
(normal or abnormal) and CAP (yes or no) and
serum and urine cortisol, respectively. All
p values of .05 or less were considered statistically significant, and no adjustment for multiplicity was made. Mean  standard deviation
were used to report the average and dispersion,
unless otherwise specified. Analysis was
performed using SPSS version 15 and JMP
version 11.

Results
There were significant differences in laboratory
and demographic data between selected
grouping factors (Table 1). Participants with CAP
had lower urine cortisol levels (p ¼ .02) and LH
levels (p ¼ .048) than those without CAP. Participants with high body fat were older than participants with low body fat (p ¼ .03). Those who
used oral contraceptives had significantly lower
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Serum AMH concentrations were negatively
correlated with age as expected (r ¼ .423,
p ¼ .01). Serum AMH, with and without adjusting
for age, was not associated with CAP, urine and
serum cortisol, and body fat. However, when AMH
was categorized as normal or abnormal (La Marca
et al., 2012), a contingency table analysis showed
that serum AMH was associated with CAP and
5-hour urinary cortisol level. Participants with
abnormal AMH levels (n ¼ 5) were more likely to
have CAP (100% vs. 38%, p ¼ .01) than those with
normal AMH levels (n ¼ 31). Participants with
abnormal AMH levels were also more likely to
have a lower 5-hour urine cortisol level (16  11
vs. 45  49, p ¼ .04) than those with normal AMH
levels (Figure 1). AMH (normal or abnormal) was
not associated with body fat percentage (p ¼ .41)
or serum cortisol (p ¼ .34).

Discussion
We found that urine cortisol levels were lower in
women with CAP. Others have reported that
chronic stress, including chronic pain, is associated with lower or blunted cortisol levels (Generaal
et al., 2014; Juster et al., 2011; Suzuki, Poon,
Papadopoulos, Kumari, & Cleare, 2014; Voellmin
et al., 2015). The lower levels of urine cortisol
observed in participants with CAP supports our
premise that CAP leads to HPA dysregulation. CAP
was also associated with lower LH levels. Others
have shown that chronic stress suppresses LH
levels, validating that CAP is a chronic stressor
(Breen, Billings, Wagenmaker, Wessinger, &
Karsch, 2005). Abnormal AMH levels were significantly associated with the presence of CAP and
lower urine cortisol levels. These findings suggest
that CAP may alter HPA activity, as expressed by
lower urine cortisol levels in women with CAP. HPA
dysregulation may contribute to ovarian dysfunction as expressed by abnormal AMH levels in
women with chronic abdominal pain. Authors of
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previous studies have shown that cortisol has
stimulatory and inhibitory effects on the ovary
(Whirledge & Cidlowski, 2013).
Further research is needed to clarify the association
between chronic physiologic and psychological
stressors, such as chronic pain and ovarian function. Understanding the biobehevioral mechanism
behind this association will improve the ability to
identify and prevent a modifiable risk factor of
premature ovarian aging. Authors of several
studies have reported negative associations between daily/acute stress levels and reproductive
function. Schliep et al. (2015) found that high daily
stress was associated with lower estradiol and LH,
as well as with higher FSH. Daily stress was also
associated with lower luteal phase progesterone
and higher odds of anovulation. Conversely, Bleil
et al. (2012b) found that psychological stress was
related to higher antral follicle count, a measure of
ovarian reserve, among younger women and
greater antral follicle count decline across women.
They proposed a model by which high stress promotes reproductive readiness in the short term (i.e.,
increased number of developing follicles) at the
cost of prematurely depleting the ovarian follicle
pool over time (Bleil et al., 2012b).
Within the context of in vitro fertilization, stress has
been associated with reduced chances to achieve
a successful pregnancy (Ebbesen et al., 2009;
Lynch, Sundaram, Maisog, Sweeney, & Buck

Anti-Müllerian hormone, as a measure of ovarian reserve,
may offer valuable insight into the enduring effects of
hypothalamic–pituitary–adrenal activity on the
reproductive system.

Louis, 2014), and the incorporation of stress
reduction interventions may improve fertility outcomes (Catherino, 2011). However, most studies
examining this association have been in populations with infertility who undergo assistive
reproductive treatments, and for this reason, it is
unclear whether stress is a biobehavioral risk factor
for the development of infertility or is secondary to
an infertility diagnosis. Improved comprehension of
the effect of prolonged stress on ovarian function
will increase our ability to counsel those for whom
stress may lead to premature ovarian aging and an
increased risk of infertility.
We also found that body fat and oral contraceptive
use were not associated with abnormal AMH
levels. Although these findings contradict the
results of prior studies (Freeman et al., 2007;
Steiner et al., 2010), this may be due to the relatively small sample size and the limited range in
body fat percentages. In addition to these main
findings, we demonstrated, to our knowledge, an
innovative way to examine the relationship
between AMH and other factors thought to affect
ovarian function. Previous researchers have

Figure 1. Urine cortisol level (5 hour) for women with normal and abnormal AMH (La Marca et al., 2012). AMH ¼
anti-Müllerian hormone; hr ¼ hour.

JOGNN 2016; Vol. 45, Issue 6
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examined AMH as a continuous variable; however, any AMH value that falls outside the
normative age-specific range (too high or too
low) is considered abnormal in the clinical
setting. This would suggest that predictors of
abnormal AMH levels might be more accurately
identified through an analysis of AMH as a
categorical variable (normal or abnormal). Additional studies are warranted to confirm the
usefulness of this statistical approach in future
research and clinical practice.

The opinions expressed herein and the interpretation and reporting of these data are the
responsibility of the author(s) and should not be
seen as an official recommendation, interpretation, or policy of the National Institutes of Health
or the United States Government.
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